SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-089654
Filing Date
2024-04-08
Accepted
2024-04-08 16:30:55
Documents
14
Period of Report
2024-04-04
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d798362d8k.htm   iXBRL 8-K 38621
2 EX-3.1 d798362dex31.htm EX-3.1 5016
  Complete submission text file 0001193125-24-089654.txt   169291

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mcrb-20240404.xsd EX-101.SCH 2868
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mcrb-20240404_lab.xml EX-101.LAB 17980
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mcrb-20240404_pre.xml EX-101.PRE 11270
17 EXTRACTED XBRL INSTANCE DOCUMENT d798362d8k_htm.xml XML 3714
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

IRS No.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37465 | Film No.: 24829982
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)